Impact Biomedical to execute 1-for-12.62 reverse stock split Sept. 23
Reuters2026/09/15 01:27- Impact Biomedical set a 1-for-12.62 reverse stock split, effective Sept. 23, 2026.
- Shares will continue trading on NYSE American under IBO.
- Outstanding shares expected to drop to about 8,543,679 from about 107,821,231, subject to rounding.
- Merger terms with Zoar call for 1 Zoar share per 1 Impact share, calculated post-split.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
